PDUFA dates and FDA Panel Review dates are very important catalysts because they are ‘make or break events’ for biotech stocks.
The goal date set by the FDA for announcing its decision on a company’s New Drug Application/ Biologics License Application/sBLA/sNDA after reviewing the applications is known as the PDUFA date.
Usually, the stocks experience a run-up going into the scheduled FDA Approval decision/FDA Panel review events. So, having prior knowledge of the key dates goes a long way toward maximizing profit or minimizing loss while investing in the volatile biotech stocks.
Listed below are large cap, mid cap and small cap stocks with pending regulatory catalysts.
Get in-depth analysis and insight on investing in the high-stakes Biotech and Pharma sectors. Check out RTT Biotech Investor and our Biotech Home Page.
ALSO READ - COVID-19 Drugs In Development Calendar which lists Companies that are in Race to find a Treatment or Vaccine for the Novel Coronavirus.
March 31, 2026 15:49 ET In this week’s video, we’ll cover major biotech moves and breakthroughs - from Novartis and Merck’s blockbuster acquisitions to the first new Hunter syndrome therapy in two decades. We’ll also look at a promising alternative to daily insulin injections and the near-term catalyst for Q3 Bio, which has been hitting new 52-week highs.
A new study from Sweden, published by the American Medical Association, has found that a single dose of psilocybin, combined with therapy sessions, can quickly reduce symptoms of depression, with benefits lasting for several months. Researchers from Karolinska Institutet and the Brain Stimulation...
Researchers have found that adding bananas to berry smoothies may greatly reduce the body's ability to absorb flavanols, healthy plant compounds linked to better heart and brain health. In a study published in the journal Food & Function, researchers tested smoothies made with ingredients containing...
The World Health Organization says the Ebola epidemic is spreading rapidly and outpacing containment efforts. There are more than 900 suspected cases of the Bundibugyo strain of Ebola in the Democratic Republic of the Congo, and 220 suspected deaths, the head of the UN health agency, Tedros Ghebreyesus,...
Silexion Therapeutics Corp. (SLXN), a clinical-stage biotechnology company in RNA interference (RNAi) therapies for KRAS-driven cancers, announced a 1-for-10 reverse share split of its ordinary shares.